公开(公告)号：US10118968B2

公开(公告)日：2018-11-06

申请号：US12649179

申请日：2009-12-29

申请人： Richard Weber ,  Xiao Feng ,  Orit Foord ,  Larry Green ,  Jean M. Gudas ,  Bruce Keyt ,  Ying Liu ,  Palaniswami Rathanaswami ,  Robert Raya ,  Xiao Dong Yang ,  Jose Corvalan ,  Ian Foltz ,  Xiao-Chi Jia ,  Jaspal S. Kang ,  Chadwick T. King ,  Scott L. Klakamp ,  Qiaojuan Jane Su

发明人： Richard Weber ,  Xiao Feng ,  Orit Foord ,  Larry Green ,  Jean M. Gudas ,  Bruce Keyt ,  Ying Liu ,  Palaniswami Rathanaswami ,  Robert Raya ,  Xiao Dong Yang ,  Jose Corvalan ,  Ian Foltz ,  Xiao-Chi Jia ,  Jaspal S. Kang ,  Chadwick T. King ,  Scott L. Klakamp ,  Qiaojuan Jane Su

IPC分类号： A61K47/48 ,  C07K16/28 ,  C12P21/08 ,  A61K39/395 ,  C07K16/30 ,  B82Y5/00 ,  A61K39/00

摘要： The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

公开(公告)号：US09580503B2

公开(公告)日：2017-02-28

申请号：US13305898

申请日：2011-11-29

申请人： Gregory M. Landes ,  Francine Chen ,  Binyam Bezabeh ,  Ian Foltz ,  Kam Fai Tse ,  Michael Jeffers ,  Mehdi Mesri ,  Gary Starling ,  Peter Mezes ,  Nikolia Khramtsov

发明人： Gregory M. Landes ,  Francine Chen ,  Binyam Bezabeh ,  Ian Foltz ,  Kam Fai Tse ,  Michael Jeffers ,  Mehdi Mesri ,  Gary Starling ,  Peter Mezes ,  Nikolia Khramtsov

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2803 ,  A61K51/1039 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2809 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/50 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/574 ,  G01N2333/70503

摘要： The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

摘要翻译： 本文描述的发明涉及针对抗原TIM-1的抗体和这种抗体的用途。 特别地，提供针对抗原TIM-1的完全人单克隆抗体。 分离的多核苷酸序列编码和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区（FR）和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是FR1至FR4 或CDR1至CDR3。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

公开(公告)号：US09238691B2

公开(公告)日：2016-01-19

申请号：US14244167

申请日：2014-04-03

申请人： Pfizer Inc. ,  Amgen Fremont Inc.

发明人： Ronald P. Gladue ,  Bradley T. Keller ,  Shinji Ogawa ,  Arvind Rajpal ,  Laurie A. Tylaska ,  Shelley Sims Belouski ,  Larry L. Green ,  Meina Liang

IPC分类号： C07K16/28 ,  A61K39/00

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

摘要： Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, preferably human CCR2, and that may inhibit CCR2. The present antibodies may bind to the first and/or second extracellular loops of CCR2. Isolated heavy and light chains derived from the antibodies and nucleic acid molecules encoding the antibodies and chains are provided. Methods of making and using the anti-CCR2 antibodies or antigen-binding portions, and compositions comprising these antibodies or antigen-binding portions, including compositions for diagnosis and treatment, are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light chains that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.

摘要翻译： 提供了包括特异性结合CCR2，优选人CCR2的人抗体和其抗原结合部分的抗体，并且可以抑制CCR2。 本抗体可以结合CCR2的第一和/或第二细胞外环。 提供衍生自抗体的分离的重链和轻链以及编码抗体和链的核酸分子。 提供制备和使用抗CCR2抗体或抗原结合部分的方法，以及包含这些抗体或抗原结合部分的组合物，包括用于诊断和治疗的组合物。 还提供了使用编码包含人抗CCR2抗体或其抗原结合部分的重链和/或轻链的核酸分子的基因治疗方法。

公开(公告)号：US08846873B2

公开(公告)日：2014-09-30

申请号：US13355366

申请日：2012-01-20

申请人： Feng Xiao ,  Xiao-Chi Jia ,  Meina Liang ,  Orit Foord ,  Scott Klakamp ,  Kam Fai Tse ,  Vincent A. Pollack ,  Luca Rastelli ,  John Herrmann ,  Henri Lichenstein ,  Michael Jeffers ,  William LaRochelle ,  Gulshan Ara ,  Peter Mezes ,  Andrei Chapoval ,  Cyrus Karkaria ,  Michael Torgov ,  Juan Davagnino

发明人： Feng Xiao ,  Xiao-Chi Jia ,  Meina Liang ,  Orit Foord ,  Scott Klakamp ,  Kam Fai Tse ,  Vincent A. Pollack ,  Luca Rastelli ,  John Herrmann ,  Henri Lichenstein ,  Michael Jeffers ,  William LaRochelle ,  Gulshan Ara ,  Peter Mezes ,  Andrei Chapoval ,  Cyrus Karkaria ,  Michael Torgov ,  Juan Davagnino

IPC分类号： C07K16/30 ,  C07K19/00 ,  C07K16/28 ,  A61K47/48 ,  A61K39/00

CPC分类号： C07K16/3053 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/94

摘要： The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

摘要翻译： 本发明提供了完全与GPNMB结合的人单克隆抗体及其应用。 提供了编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列。 本发明还提供了包含抗GPNMB抗体的免疫缀合物和使用这种免疫缀合物的方法。 本发明还提供了包含抗GPNMB抗体组分和抗-CD3组分的双特异性抗体，以及使用这种双特异性抗体的方法。

公开(公告)号：US08642037B2

公开(公告)日：2014-02-04

申请号：US13169474

申请日：2011-06-27

申请人： Bruce D. Cohen ,  Jean Beebe ,  Penelope E. Miller ,  James D. Moyer ,  Jose Ramon Corvalan ,  Michael Gallo

发明人： Bruce D. Cohen ,  Jean Beebe ,  Penelope E. Miller ,  James D. Moyer ,  Jose Ramon Corvalan ,  Michael Gallo

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/2863 ,  A01K2217/05 ,  A61K31/138 ,  A61K31/513 ,  A61K31/517 ,  A61K31/704 ,  A61K39/39541 ,  A61K39/39558 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/72 ,  C07K16/30 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/574 ,  G01N33/57492 ,  G01N2333/65 ,  G01N2333/71 ,  A61K2300/00

摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.

摘要翻译： 本发明涉及特异性结合胰岛素样生长因子I受体（IGF-1R）的抗体及其抗原结合部分，其优选为人IGF-1R。 本发明还涉及人抗IGF-1R抗体，包括嵌合，双特异性，衍生的单链抗体或融合蛋白的部分。 本发明还涉及衍生自抗IGF-1R抗体和编码这种分子的核酸分子的分离的重链和轻链免疫球蛋白分子。 本发明还涉及制备抗IGF-1R抗体的方法，包含这些抗体的药物组合物和使用抗体及其组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗IGF-1R抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的基因治疗方法和转基因动物。

公开(公告)号：US08568992B2

公开(公告)日：2013-10-29

申请号：US13480356

申请日：2012-05-24

申请人： Wynn L. Walker ,  Michael L. Gallo ,  Xiao-Chi Jia ,  Keith Joho ,  Jaspal Singh Kang

发明人： Wynn L. Walker ,  Michael L. Gallo ,  Xiao-Chi Jia ,  Keith Joho ,  Jaspal Singh Kang

IPC分类号： G01N33/53

CPC分类号： G01N33/543 ,  G01N33/54306 ,  G01N33/58 ,  G01N33/6878 ,  G06F17/16 ,  G06F19/24

摘要： Methods for categorizing antibodies based on their epitope binding characteristics are described. Methods and systems for determining the epitope recognition properties of different antibodies are provided. Also provided are data analysis processes for clustering antibodies on the basis of their epitope recognition properties and for identifying antibodies having distinct epitope binding characteristics.

公开(公告)号：US08188249B2

公开(公告)日：2012-05-29

申请号：US12748602

申请日：2010-03-29

申请人： Vahe Bedian ,  Madhav Narasimha Devalaraja ,  Ian Foltz ,  Mary Haak-Frendscho ,  Sirid-Aimee Kellermann ,  Joseph Edwin Low ,  James Leslie Mobley

发明人： Vahe Bedian ,  Madhav Narasimha Devalaraja ,  Ian Foltz ,  Mary Haak-Frendscho ,  Sirid-Aimee Kellermann ,  Joseph Edwin Low ,  James Leslie Mobley

IPC分类号： C07H21/04 ,  C12N15/00 ,  C12N5/07 ,  C12N5/16

CPC分类号： C07K16/243 ,  A61K38/193 ,  A61K39/395 ,  A61K2039/505 ,  C07K16/24 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G06Q30/02 ,  G06Q30/0601 ,  G06Q40/04 ,  G06Q50/12 ,  Y02A50/412

摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.

摘要翻译： 本发明涉及特异性结合M-CSF，优选人M-CSF的抗体及其抗原结合部分，其功能是抑制M-CSF。 本发明还涉及人抗M-CSF抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗M-CSF抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗M-CSF抗体的方法，包含这些抗体的组合物和使用该抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗M-CSF抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物和转基因植物。

公开(公告)号：US08114965B2

公开(公告)日：2012-02-14

申请号：US11983372

申请日：2007-11-07

申请人： Paul J. Maddon ,  Gerald P. Donovan ,  William C. Olson ,  Norbert Schuelke ,  Jason Gardner ,  Dangshe Ma ,  Jaspal S. Kang ,  Larry Green

发明人： Paul J. Maddon ,  Gerald P. Donovan ,  William C. Olson ,  Norbert Schuelke ,  Jason Gardner ,  Dangshe Ma ,  Jaspal S. Kang ,  Larry Green

IPC分类号： C07K16/18

CPC分类号： A61K51/1096 ,  A61K47/6825 ,  A61K47/6869 ,  A61K51/1072 ,  A61K2039/505 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/622

摘要： The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.

摘要翻译： 本发明包括与PSMA细胞外结构域上的构象表位特异性结合的抗体或其抗原结合片段，含有一种或其组合的抗体或其抗原结合片段，产生抗体的杂交瘤细胞系， 使用抗体或其抗原结合片段进行癌症诊断和治疗。 本发明还包括PSMA蛋白的寡聚形式，包含多聚体的组合物和选择性结合多聚体的抗体。

公开(公告)号：US20110274696A1

公开(公告)日：2011-11-10

申请号：US13059702

申请日：2009-08-17

申请人： Ronald P. Gladue ,  Bradley T. Keller ,  Shinji Ogawa ,  Arvind Rajpal ,  Laurie A. Tylaska ,  Shelley Sims Belouski ,  Larry L. Green ,  Meina Liang

发明人： Ronald P. Gladue ,  Bradley T. Keller ,  Shinji Ogawa ,  Arvind Rajpal ,  Laurie A. Tylaska ,  Shelley Sims Belouski ,  Larry L. Green ,  Meina Liang

IPC分类号： A61K39/395 ,  C07H21/00 ,  C12N15/63 ,  C12N5/16 ,  C12N5/10 ,  C12N1/21 ,  C12N1/19 ,  A61P29/00 ,  A61P37/08 ,  A61P37/06 ,  A61P9/10 ,  A61P3/10 ,  A61P31/18 ,  A61P25/00 ,  A61P9/00 ,  A61P25/28 ,  A61P43/00 ,  A61P35/00 ,  A61P27/02 ,  A61P1/16 ,  C07K16/28

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

摘要： Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CCR2 antibodies or antigen binding portions thereof

摘要翻译： 提供了抗体，其包括特异性结合CCR2的人抗体及其抗原结合部分，特别是人CCR2，并且其可能起抑制CCR2的作用。 抗CCR2抗体包括结合CCR2的第一和/或第二细胞外环的那些抗体。 还提供了人抗CCR2抗体及其抗原结合部分。 提供衍生自人抗CCR2抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 提供制备人抗CCR2抗体或抗原结合部分的方法，包含这些抗体或抗原结合部分的组合物，使用抗体和抗原结合部分的方法，以及用于诊断和治疗的组合物。 还提供了使用编码包含人抗CCR2抗体或其抗原结合部分的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法

公开(公告)号：US07964193B2

公开(公告)日：2011-06-21

申请号：US12456660

申请日：2009-06-19

申请人： Larry Green ,  Raffaella Faggioni ,  Orit Foord ,  Scott L. Klakamp ,  Giorgio Senaldi ,  Amy K. Schneider

发明人： Larry Green ,  Raffaella Faggioni ,  Orit Foord ,  Scott L. Klakamp ,  Giorgio Senaldi ,  Amy K. Schneider

IPC分类号： A61K39/395

CPC分类号： C07K16/245 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  Y10S424/801 ,  Y10S530/867

摘要： Antibodies directed to the antigen IL-1β and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen IL-1β. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

摘要翻译： 针对抗原IL-1和bgr的抗体 并描述了这些抗体的用途。 特别是针对抗原IL-1和bgr的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 。 表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。